Details of the Drug
General Information of Drug (ID: DM457XO)
Drug Name |
IW-1701
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Olinciguat; 1628732-62-6; UNII-PD5F4ZXD21; PD5F4ZXD21; IW1701; 5-(1,2-oxazol-3-yl)-1H-pyrazol-; 3-yl}pyrimidin-4-yl)amino]methyl}-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-{[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-; Olinciguat [INN]; Olinciguat [USAN]; Olinciguat (USAN/INN); Olinciguat [USAN:INN]; CHEMBL4297616; SCHEMBL16081945; GTPL10213; BDBM321744; DB15238; US10183021, Compound I-531; AC-31551; HY-109066; CS-0033431; D11475; (2~{R})-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure |
![]() |
|||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 2 | Molecular Weight (mw) | 509.4 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 2.3 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 8 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 13 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
References